| Carlos Vieira, MD | |
|
2326 18th St Ste 230, Columbus, IN 47201-5359 | |
| (812) 375-5710 | |
| Not Available |
| Full Name | Carlos Vieira |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 28 Years |
| Location | 2326 18th St Ste 230, Columbus, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164463949 | NPI | - | NPPES |
| 200506510 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 01053351 (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Columbus Regional Hospital | Columbus, IN | Hospital |
| Major Hospital | Shelbyville, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Columbus Regional Health Physicians Llc | 1052612314 | 192 |
| Major Multispecialty Associates | 6305997842 | 44 |
News Archive
"This week, PATH and our partners celebrated the official launch of the production line for a new synthetic version of artemisinin, the key ingredient for the gold-standard malaria treatment - one that plays a major role in protecting the lives of children and adults worldwide," PATH President and CEO Steve Davis writes in the Bill & Melinda Gates Foundation's "Impatient Optimists" blog.
40 percent of people in the EU suffer from non-alcoholic steatohepatitis (fatty liver disease), a disease which is becoming increasingly more frequent as a result of diabetes and excess weight in an affluent society. Currently, it is not possible to forecast the further course of the disease - right up to cirrhosis and cancer of the liver. Furthermore, an increased risk of heart attack and kidney damage exists. In future, this should become possible using a Risk Score with different biomarkers.
Intercell AG today announced that it has signed an agreement with Cytos Biotechnology Ltd. to acquire Cytos' platform technology for monoclonal antibody discovery. The technology is based on expression cloning of monoclonal antibodies from human B-cells and enables the identification of anti-infective antibodies to prevent and treat infectious diseases.
People given large servings of food eat more than those given smaller servings, even after they have been taught about the impact of portion size on consumption, research from the University of New South Wales shows.
A new study from Stanford, published on December 12 in the journal Acta Neuropathologica Communications, suggests that an important enzyme that helps break down alcohol in the body is defective in patients with Alzheimer's disease (AD). Understanding its relationship with alcohol and with genes that predispose to AD could help avert the latter in humans at risk.
› Verified 7 days ago
| Entity Name | Rush Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497726020 PECOS PAC ID: 7012802754 Enrollment ID: O20040220000164 |
News Archive
"This week, PATH and our partners celebrated the official launch of the production line for a new synthetic version of artemisinin, the key ingredient for the gold-standard malaria treatment - one that plays a major role in protecting the lives of children and adults worldwide," PATH President and CEO Steve Davis writes in the Bill & Melinda Gates Foundation's "Impatient Optimists" blog.
40 percent of people in the EU suffer from non-alcoholic steatohepatitis (fatty liver disease), a disease which is becoming increasingly more frequent as a result of diabetes and excess weight in an affluent society. Currently, it is not possible to forecast the further course of the disease - right up to cirrhosis and cancer of the liver. Furthermore, an increased risk of heart attack and kidney damage exists. In future, this should become possible using a Risk Score with different biomarkers.
Intercell AG today announced that it has signed an agreement with Cytos Biotechnology Ltd. to acquire Cytos' platform technology for monoclonal antibody discovery. The technology is based on expression cloning of monoclonal antibodies from human B-cells and enables the identification of anti-infective antibodies to prevent and treat infectious diseases.
People given large servings of food eat more than those given smaller servings, even after they have been taught about the impact of portion size on consumption, research from the University of New South Wales shows.
A new study from Stanford, published on December 12 in the journal Acta Neuropathologica Communications, suggests that an important enzyme that helps break down alcohol in the body is defective in patients with Alzheimer's disease (AD). Understanding its relationship with alcohol and with genes that predispose to AD could help avert the latter in humans at risk.
› Verified 7 days ago
| Entity Name | Major Multispecialty Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437398492 PECOS PAC ID: 6305997842 Enrollment ID: O20090624000134 |
News Archive
"This week, PATH and our partners celebrated the official launch of the production line for a new synthetic version of artemisinin, the key ingredient for the gold-standard malaria treatment - one that plays a major role in protecting the lives of children and adults worldwide," PATH President and CEO Steve Davis writes in the Bill & Melinda Gates Foundation's "Impatient Optimists" blog.
40 percent of people in the EU suffer from non-alcoholic steatohepatitis (fatty liver disease), a disease which is becoming increasingly more frequent as a result of diabetes and excess weight in an affluent society. Currently, it is not possible to forecast the further course of the disease - right up to cirrhosis and cancer of the liver. Furthermore, an increased risk of heart attack and kidney damage exists. In future, this should become possible using a Risk Score with different biomarkers.
Intercell AG today announced that it has signed an agreement with Cytos Biotechnology Ltd. to acquire Cytos' platform technology for monoclonal antibody discovery. The technology is based on expression cloning of monoclonal antibodies from human B-cells and enables the identification of anti-infective antibodies to prevent and treat infectious diseases.
People given large servings of food eat more than those given smaller servings, even after they have been taught about the impact of portion size on consumption, research from the University of New South Wales shows.
A new study from Stanford, published on December 12 in the journal Acta Neuropathologica Communications, suggests that an important enzyme that helps break down alcohol in the body is defective in patients with Alzheimer's disease (AD). Understanding its relationship with alcohol and with genes that predispose to AD could help avert the latter in humans at risk.
› Verified 7 days ago
| Entity Name | Columbus Regional Health Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336510098 PECOS PAC ID: 1052612314 Enrollment ID: O20151211000054 |
News Archive
"This week, PATH and our partners celebrated the official launch of the production line for a new synthetic version of artemisinin, the key ingredient for the gold-standard malaria treatment - one that plays a major role in protecting the lives of children and adults worldwide," PATH President and CEO Steve Davis writes in the Bill & Melinda Gates Foundation's "Impatient Optimists" blog.
40 percent of people in the EU suffer from non-alcoholic steatohepatitis (fatty liver disease), a disease which is becoming increasingly more frequent as a result of diabetes and excess weight in an affluent society. Currently, it is not possible to forecast the further course of the disease - right up to cirrhosis and cancer of the liver. Furthermore, an increased risk of heart attack and kidney damage exists. In future, this should become possible using a Risk Score with different biomarkers.
Intercell AG today announced that it has signed an agreement with Cytos Biotechnology Ltd. to acquire Cytos' platform technology for monoclonal antibody discovery. The technology is based on expression cloning of monoclonal antibodies from human B-cells and enables the identification of anti-infective antibodies to prevent and treat infectious diseases.
People given large servings of food eat more than those given smaller servings, even after they have been taught about the impact of portion size on consumption, research from the University of New South Wales shows.
A new study from Stanford, published on December 12 in the journal Acta Neuropathologica Communications, suggests that an important enzyme that helps break down alcohol in the body is defective in patients with Alzheimer's disease (AD). Understanding its relationship with alcohol and with genes that predispose to AD could help avert the latter in humans at risk.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carlos Vieira, MD Po Box 775383, Chicago, IL 60677-5383 Ph: (812) 376-5315 | Carlos Vieira, MD 2326 18th St Ste 230, Columbus, IN 47201-5359 Ph: (812) 375-5710 |
News Archive
"This week, PATH and our partners celebrated the official launch of the production line for a new synthetic version of artemisinin, the key ingredient for the gold-standard malaria treatment - one that plays a major role in protecting the lives of children and adults worldwide," PATH President and CEO Steve Davis writes in the Bill & Melinda Gates Foundation's "Impatient Optimists" blog.
40 percent of people in the EU suffer from non-alcoholic steatohepatitis (fatty liver disease), a disease which is becoming increasingly more frequent as a result of diabetes and excess weight in an affluent society. Currently, it is not possible to forecast the further course of the disease - right up to cirrhosis and cancer of the liver. Furthermore, an increased risk of heart attack and kidney damage exists. In future, this should become possible using a Risk Score with different biomarkers.
Intercell AG today announced that it has signed an agreement with Cytos Biotechnology Ltd. to acquire Cytos' platform technology for monoclonal antibody discovery. The technology is based on expression cloning of monoclonal antibodies from human B-cells and enables the identification of anti-infective antibodies to prevent and treat infectious diseases.
People given large servings of food eat more than those given smaller servings, even after they have been taught about the impact of portion size on consumption, research from the University of New South Wales shows.
A new study from Stanford, published on December 12 in the journal Acta Neuropathologica Communications, suggests that an important enzyme that helps break down alcohol in the body is defective in patients with Alzheimer's disease (AD). Understanding its relationship with alcohol and with genes that predispose to AD could help avert the latter in humans at risk.
› Verified 7 days ago
David Chiapaikeo, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2109 Doctors Park Dr, Columbus, IN 47203 Phone: 812-372-2245 Fax: 812-375-2156 | |
Michael J Dorenbusch, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 2325 18th St Ste 220, Columbus, IN 47201 Phone: 812-376-5640 Fax: 812-376-5641 | |
Cory Banaschak, Surgery Medicare: Accepting Medicare Assignments Practice Location: 2325 18th St Ste 220, Columbus, IN 47201 Phone: 812-376-5640 | |
Dr. Justin James Burdick, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2325 18th St Ste 220, Columbus, IN 47201 Phone: 812-376-5640 | |
Dr. Jason Wayne Christie, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2109 Doctors Park Dr, Columbus, IN 47203 Phone: 812-372-2245 | |
Dr. John David Lipson, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 12945 E 100 N, Columbus, IN 47203 Phone: 812-579-9024 |